Comprehensive medication guide to Caplyta including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
With commercial insurance and the Caplyta Savings Card, eligible patients may pay as little as $15 per prescription, though typical copays without a savings card range from $50 to $150 per month after prior authorization.
Estimated Cash Pricing
The cash price for Caplyta (lumateperone) 42 mg capsules is approximately $1,650 to $1,800 per month (30 capsules) without insurance.
Medfinder Findability Score
55/100
Summarize with AI
On this page
Caplyta (lumateperone) is an atypical antipsychotic medication manufactured by Intra-Cellular Therapies, now part of Johnson & Johnson. It is FDA-approved for:
Caplyta is taken as a once-daily oral capsule at a standard dose of 42 mg. No dose titration is needed. It can be taken with or without food.
![Why is Caplyta so hard to find? [Explained for 2026]](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2Fvur4atr4%2Fproduction%2F97142cbcfb3aa94558427a1c13c507e3e8f6fc1b-1024x1024.png%3Frect%3D0%2C256%2C1024%2C512%26w%3D400%26h%3D200%26auto%3Dformat&w=828&q=75)
![How to Find a Doctor Who Can Prescribe Caplyta Near You [2026 Guide]](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2Fvur4atr4%2Fproduction%2F1f4988dd5373520afef7f6cda463c05f2e71138d-1024x1024.png%3Frect%3D0%2C256%2C1024%2C512%26w%3D400%26h%3D200%26auto%3Dformat&w=828&q=75)
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Caplyta (lumateperone) is a multitarget agent that modulates three major neurotransmitter systems in the brain:
Caplyta also has moderate serotonin transporter (SERT) inhibition activity, which may contribute to its antidepressant effects. This unique mechanism across serotonin, dopamine, and glutamate pathways distinguishes it from older antipsychotics and may explain its favorable tolerability profile with less weight gain and metabolic effects than many other atypical antipsychotics.
Take one capsule by mouth once daily. Swallow the capsule whole — do not crush, chew, or open it.
10.5 mg capsules
for patients on strong CYP3A4 inhibitors
21 mg capsules
for patients on moderate CYP3A4 inhibitors or with hepatic impairment
42 mg capsules
standard dose for most patients
Caplyta scores a 55 out of 100 on our findability scale, meaning it's moderately difficult to find and may require some effort to locate. Caplyta is not currently listed on the FDA or ASHP drug shortage databases, and there are no active supply disruptions.
However, as a brand-only specialty medication manufactured solely by Intra-Cellular Therapies (now part of Johnson & Johnson), not every pharmacy carries it in stock. Caplyta's expanding indications — now covering schizophrenia, bipolar depression, and adjunctive MDD treatment — have increased demand, which can lead to temporary stock-outs at individual pharmacies.
Use Medfinder to quickly locate which pharmacies near you have Caplyta in stock.
Caplyta is typically prescribed by:
Telehealth consultations are available for Caplyta prescriptions, making it accessible for ongoing management. Initial evaluations typically require a comprehensive psychiatric assessment.
No. Caplyta is not a controlled substance and does not have a DEA schedule. It is a prescription-only medication but does not carry the restrictions associated with controlled substances.
However, Caplyta carries a boxed warning regarding increased risk of death in elderly patients with dementia-related psychosis (it is not approved for this use) and increased risk of suicidal thoughts and behaviors in pediatric and young adult patients when used for depression. Patients should be monitored for clinical worsening and emergence of suicidal thoughts.
The most frequently reported side effects include:
Serious side effects (seek medical attention immediately):
Know what you need? Skip the search.
Latuda (lurasidone)
approved for schizophrenia and bipolar depression, with a generic available at significantly lower cost
Vraylar (cariprazine)
approved for schizophrenia, bipolar depression, and bipolar mania
Rexulti (brexpiprazole)
approved for schizophrenia and adjunctive MDD treatment
Seroquel (quetiapine)
approved for schizophrenia, bipolar depression, and adjunctive MDD, with a generic available
Prefer Caplyta? We can find it.
Strong CYP3A4 inhibitors
moderate(ketoconazole, clarithromycin, itraconazole) — requires dose reduction to 10.5 mg daily
Moderate CYP3A4 inhibitors
moderate(diltiazem, erythromycin, fluconazole) — requires dose reduction to 21 mg daily
CYP3A4 inducers
moderate(carbamazepine, rifampin, St. John's wort) — avoid concomitant use
Serotonergic drugs
moderate(SSRIs, SNRIs) — increased risk of serotonin syndrome and hyponatremia
Other CNS depressants
moderateadditive sedation
Antihypertensives
moderateadditive hypotensive effects
Anticholinergic drugs
moderateadditive effects
Caplyta is a newer atypical antipsychotic with a unique mechanism of action spanning serotonin, dopamine, and glutamate systems. Its expanding FDA-approved indications — now including schizophrenia, bipolar depression, and adjunctive MDD treatment — make it an increasingly versatile option in psychiatry. Many clinicians favor it for its favorable side effect profile, with less weight gain and metabolic disruption than older antipsychotics.
The biggest challenge with Caplyta is cost. At $1,650–$1,800 per month without insurance and no generic available, it's a significant expense. However, the Caplyta Savings Card can bring the cost down to as little as $15 per fill for commercially insured patients. Uninsured patients should explore the Johnson & Johnson Patient Assistance Program for potential no-cost access.
Use Medfinder to locate pharmacies near you that have Caplyta in stock, and check coupon platforms like GoodRx and SingleCare for additional savings.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini